Ipamorelin

What Ipamorelin Does

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue — it triggers your pituitary gland to release growth hormone. What makes it special isn’t that it releases GH (several peptides do that), but that it does so with remarkable selectivity. It is the cleanest GH-releasing peptide available.

The mechanisms that matter:

• Selective ghrelin receptor agonism — binds to GHS-R1a receptors on pituitary somatotrophs, triggering GH release without significantly activating cortisol, prolactin, or ACTH pathways. This is Ipamorelin’s defining advantage over older GHRPs.
• Pulsatile GH release — produces a natural, pulse-like GH spike that mimics physiological secretion patterns, unlike exogenous HGH which creates a flat, supraphysiological plateau
• IGF-1 elevation — the downstream effect. Higher GH drives hepatic IGF-1 production, which mediates muscle protein synthesis, fat oxidation, collagen production, and cellular repair
• Synergy with GHRH analogs — Ipamorelin (a GHRP) works on the ghrelin receptor pathway. CJC-1295 (a GHRH) works on the GHRH receptor pathway. Combined, they produce 3–5x greater GH release than either alone — this is why the stack is standard

Why Ipamorelin Over Other GHRPs

There are several growth hormone releasing peptides. Here’s why Ipamorelin is the preferred choice:

Peptide	GH Release	Appetite Spike	Cortisol Increase	Prolactin Increase
Ipamorelin	Moderate	Minimal	None at standard dose	None at standard dose
GHRP-2	Strong	Moderate	Mild elevation	Mild elevation
GHRP-6	Strong	Severe	Moderate elevation	Mild elevation
Hexarelin	Very strong	Mild	Significant	Significant

Ipamorelin trades slightly less raw GH output for a dramatically cleaner side effect profile. For most users — especially those prioritizing anti-aging, sleep, and body composition over maximum GH output — this tradeoff is worth it.

GHRP-6 causes intense hunger spikes that can derail body composition goals. Hexarelin causes cortisol and prolactin elevation and shows desensitization within weeks. GHRP-2 is a middle ground but still inferior to Ipamorelin for clean, sustainable GH release.

Dosing Protocol

Standard Protocol (With CJC-1295)

Parameter	Detail
Dose	100 mcg Ipamorelin + 100 mcg CJC-1295 (no DAC) per injection
Frequency	2–3 times daily
Best timing	Morning (fasted), post-workout, pre-sleep
Cycle length	8–12 weeks on, 4 weeks off
Route	Subcutaneous injection

The pre-sleep dose is the most important. It amplifies the natural nocturnal GH surge — the largest GH pulse of the day. If you can only inject once daily, do it 30 minutes before bed on an empty stomach.

Dose Tiers

Level	Ipamorelin Dose	Best For
Conservative	100 mcg, 1–2x daily	Anti-aging, sleep improvement, general wellness
Standard	100 mcg, 3x daily	Body composition, recovery, comprehensive GH optimization
Aggressive	200–300 mcg, 2–3x daily	Advanced users prioritizing body recomposition

Start conservative. Most benefits come from the 100 mcg dose. Higher doses increase side effects (water retention, tingling) without proportionally increasing benefits. The law of diminishing returns hits hard above 200 mcg per dose.

Fasting Requirements

This is non-negotiable for GH peptides:

• Fast 2+ hours before injection — elevated insulin suppresses GH release at the pituitary level
• Wait 30–60 minutes after injection before eating — allow the GH pulse to complete
• No carbs are the biggest offender — protein has less impact, but full fasting is safest
• Pre-sleep window is naturally fasted — this is why most beginners start with a single bedtime dose

Ipamorelin Alone (Without CJC-1295)

Parameter	Detail
Dose	200–300 mcg per injection
Frequency	2–3 times daily
Cycle length	8–12 weeks on, 4 weeks off

Running Ipamorelin alone requires higher doses to compensate for the missing GHRH signal. It works, but the GH release is modest. The CJC-1295 combination is strongly recommended for meaningful results.

Reconstitution

For a 5 mg vial of Ipamorelin — add 2.5 mL bacteriostatic water:

Dose	Volume to Draw
100 mcg	5 units on insulin syringe
200 mcg	10 units on insulin syringe
300 mcg	15 units on insulin syringe

This gives a concentration of 2,000 mcg/mL. One 5 mg vial provides 50 doses at 100 mcg — roughly 17–25 days depending on frequency.

Combining with CJC-1295: You can draw Ipamorelin and CJC-1295 from separate vials into the same syringe and inject together. Draw the first peptide, then insert the same needle into the second vial and draw the second. Inject immediately — never pre-mix vials for storage.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted powder can be frozen for long-term storage.

Use Cases

Goal	Protocol Notes
Anti-aging / longevity	100 mcg + CJC 100 mcg, pre-sleep only, 12 weeks
Sleep optimization	100 mcg + CJC 100 mcg, pre-sleep, 8–12 weeks
Body recomposition	100 mcg + CJC 100 mcg, 3x daily, 12 weeks
Injury recovery support	100 mcg + CJC 100 mcg, 2x daily, 8–12 weeks (stack with BPC-157 for accelerated healing)
Skin and hair quality	100 mcg + CJC 100 mcg, 2x daily, 12 weeks (GH drives collagen synthesis)

What the Research Says

Ipamorelin has strong preclinical data and meaningful human clinical evidence:

Human clinical data:

• A Phase II randomized controlled trial in post-surgical patients showed Ipamorelin (0.01 mg/kg IV) accelerated recovery of bowel function following abdominal surgery. The study confirmed GH-releasing activity with a favorable safety profile — no significant changes in cortisol, prolactin, FSH, LH, or TSH. (Clinical Endocrinology, 2005)
• Dose-response studies demonstrated that Ipamorelin produces dose-dependent GH release in healthy subjects, with peak GH levels occurring 30–45 minutes post-injection and returning to baseline within 2–3 hours

Selectivity data:

• Comparative studies show Ipamorelin produces GH release comparable to GHRP-6 but without the cortisol and prolactin spikes that characterize other GHRPs. This selectivity has been confirmed across multiple research groups and is the peptide’s primary differentiator.

Synergy research:

• The combination of GHRH analogs (like CJC-1295) and GHRPs (like Ipamorelin) produces synergistic GH release — the combined effect exceeds the sum of individual effects. This pharmacological synergy is well-established and forms the basis for the standard GH peptide stack.

Key practitioners:

• Derek (More Plates More Doses) recommends the CJC-1295/Ipamorelin combination as the go-to GH peptide protocol for body composition and anti-aging
• Multiple anti-aging clinics prescribe Ipamorelin as a first-line GH secretagogue due to its clean side effect profile

Safety

Common Side Effects

Ipamorelin has the cleanest side effect profile of any GH secretagogue:

• Water retention — mild, especially in the first 2–3 weeks. Indicates GH elevation. Usually resolves.
• Numbness/tingling in extremities — carpal tunnel-like symptoms. Dose-dependent. Reduce dose if persistent.
• Injection-site reactions — minor redness, itching, or soreness. Rotate sites.
• Headaches — occasional, usually mild and transient.
• Increased hunger — GH naturally stimulates appetite. Less pronounced than GHRP-6 but present.
• Vivid dreams — commonly reported with the pre-sleep dose. Most users consider this a positive effect.
• Improved sleep depth — deeper, more restorative sleep. Onset within the first week for many users.

What Ipamorelin Does NOT Do (Unlike Other GHRPs)

• Does not spike cortisol — no stress hormone elevation at standard doses
• Does not raise prolactin — no gynecomastia risk from prolactin
• Does not cause severe hunger — unlike GHRP-6, appetite increase is manageable
• Does not rapidly desensitize — unlike Hexarelin, which shows reduced response within 2 weeks

Critical Warnings

Fasting is mandatory. Insulin suppresses GH release. Injecting in a fed state wastes the peptide.

Not FDA-approved. Ipamorelin is not approved for human therapeutic use in any jurisdiction. All use is experimental.

Banned by WADA. Tested athletes cannot use Ipamorelin.

Cancer precaution. Growth hormone promotes cell growth. Do not use with active malignancies, recent cancer history, or significant cancer risk factors.

Source quality. Only purchase from vendors providing third-party CoA with HPLC purity testing and mass spectrometry confirmation.

Do Not Use If

• Active cancer or tumor history
• Active acromegaly or pituitary tumors
• Type 1 diabetes (GH affects insulin sensitivity — monitor closely with Type 2)
• Pregnant or breastfeeding
• Under 18 (growth plates still active — GH peptides can cause disproportionate growth)
• Subject to WADA/USADA testing

What Comes Next

Ipamorelin is most effective as part of a stack:

• Pair with CJC-1295 in the Growth Hormone Stack — the gold standard GH peptide combination
• Compare GH options in our Growth Hormone Peptides Compared guide
• Consider MK-677 as an oral GH booster — see the MK-677 Protocol
• Use the Reconstitution Calculator for exact unit counts